The Effects of Trans Venous Cardiac Pacing on Coronary Microvascular Function and Hemodynamics

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03917251

Enrollment

Registered

2019-04-17

Start date

2021-10-07

Completion date

2021-10-07

Last updated

2024-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Pacemaker Syndrome, Coronary Microvascular Disease

Keywords

coronary microvascular dysfunction

Brief summary

The study will examine role of transvenous pacing on coronary microcirculation.

Detailed description

To study the role of transvenous pacing on the coronary microcirculation. This will be accomplished by gathering data from invasive Fractional Flow Reserve (FFR) and Coronary Flow Reserve (CFR) with and without ventricular pacing.

Interventions

DIAGNOSTIC_TESTCoronary flow and pressure measurement in patients with ventricular pacing

Coronary flow and pressure measurement in patients with ventricular pacing

Study design

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

All patients 19 years of age or older with clinical evidence of coronary ischemia undergoing coronary angiogram, and who have a pacemaker.

Exclusion criteria

* Acute ST segment myocardial infarction * Known sensitivity or contraindication to the agents planned for administration during coronary angiography * Pacemaker dependent patients * Pregnancy * Hypotension (a systolic blood pressure lower than 90mmHg) that would preclude the administration of adenosine * Severe renal dysfunction, defined as a estimated glomerular filtration (eGFR) less than 30ml/min, confirmed by recent testing * Study subject has any underlying disorder that, in the opinion of the investigator, precludes them from giving informed consent at the time of enrollment

Design outcomes

Primary

Measure	Time frame	Description
Patients that exhibit coronary microvascular resistance and dysfunction as reflected by FFR	Up to 12 months	Microvascular dysfunction with pacing

Secondary

Measure	Time frame	Description
Patients that exhibit coronary microvascular resistance and dysfunction as reflected by CFR	Up to 12 months	Microvascular dysfunction with pacing

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026